What is Senti Bio?
Headquartered in South San Francisco, Senti Bio is at the forefront of the synthetic biology revolution. The company specializes in the creation of gene circuits—novel, proprietary DNA sequences that function as biological software. These circuits enable the reprogramming of cells to perform sophisticated tasks, effectively turning them into intelligent therapeutic agents. By integrating these circuits into cell and gene therapies, Senti Bio aims to address some of the most challenging medical conditions, providing a level of precision and control previously unattainable in traditional biotechnology. Their market position is bolstered by a robust intellectual property portfolio and a collaborative ecosystem of investors spanning the life sciences and technology sectors.
How much funding has Senti Bio raised?
Senti Bio has raised a total of $183.2M across 5 funding rounds:
Series A
$53M
Series B
$105M
Debt
$5.2M
Other Financing Round
$10M
Debt
$10M
Series A (2018): $53M with participation from Goodman Capital, Lifeforce Capital Gp I, Nest.Bio, New Enterprise Associates, Menlo Ventures, Allen & Company, Pear Ventures, Omega Funds, Lux Capital, 8VC, and Amgen Business Development
Series B (2021): $105M led by Intel Capital, Leaps by Bayer, Ridgeback Capital, Mirae Asset Capital Co,Ltd, and Matrix Partners China
Debt (2022): $5.2M supported by Bayer
Other Financing Round (2025): $10M featuring Celadon Partners
Debt (2026): $10M, investors not publicly disclosed
Key Investors in Senti Bio
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
Lux Capital
Lux Capital is a New York based venture capital firm that raises dedicated funds to invest in earlystage and growthstage companies at the intersection of science and technology.
Intel Capital
Founded in 1991, Intel Capital, a division of Intel, invests in innovative startups targeting artificial intelligence, autonomous vehicles, datacenter, Cloud, 5G, and next-generation compute.
What's next for Senti Bio?
Looking ahead, Senti Bio is poised to leverage its $10M strategic investment to scale its clinical pipeline and refine its gene circuit technology. The company's roadmap focuses on transitioning its lead candidates through rigorous clinical validation while simultaneously expanding its platform capabilities to address a broader range of therapeutic indications. As the firm moves deeper into the enterprise-level growth phase, the focus will likely shift toward strategic partnerships and potential commercialization pathways. The continued support from diverse investors suggests a long-term commitment to establishing Senti Bio as a dominant force in the programmable medicine landscape, with a clear trajectory toward transforming the standard of care for patients worldwide.
See full Senti Bio company page
